Ceritinib

色瑞替尼

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameCeritinib
Drug Alias Nameceritinibum塞瑞替尼certinib塞利替尼ceritinib +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInsulin receptor inhibitorsProto-oncogene tyrosine-protein kinase ROS inhibitorsAnaplastic lymphoma kinase inhibitors +[4] 
TargetsInsulin-like growth factor I receptorAnaplastic lymphoma kinaseProto-oncogene tyrosine-protein kinase ROS +[4] 
Therapy Area/IndicationsBrain metastasesEsophageal adenocarcinomaLiver Dysfunction +[18] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryUnited States
Original Approved Date2014/04/29
Country/TerritoryCzechiaBelgiumBulgaria +[41] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesH Lee Moffitt Cancer Center & Research InstituteNovartis Pharma AgBeOne Medicines Ltd +[4] 
Inactive CompaniesUniversity of Texas Southwestern Medical CenterNational Health Research InstitutesYonsei University +[6] 
Active IndicationsCarcinoma, Non-Small-Cell LungMelanoma
Inactive IndicationsBrain metastasesEsophageal adenocarcinomaLiver Dysfunction +[16] 

Other Information

ATC CodeL01ED02
Related LinksWikipediaDrugBankKEGG